Clinical trials: Dialysis
Chronic Kidney Disease, Chronic Renal Insufficiency
STAAR-2 Clinical Study
To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.
- Conditions
- Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease, Pre-dialysis
- Trial name
- NCT00368901
- Testing
- Darbepoetin alfa
- Volunteers
- 618 people
- Sponsor
- Amgen
Chronic Kidney Disease, Chronic Renal Insufficiency
STAAR-3 Clinical Study
To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.
- Conditions
- Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease, Pre-dialysis
- Trial name
- NCT00369733
- Testing
- Darbepoetin alfa
- Volunteers
- 443 people
- Sponsor
- Amgen
Renal Dialysis, Pharmacokinetics
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3.
- Trial name
- NCT00730145
- Testing
- PD-0332334
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Chronic Kidney Disease, Chronic Renal Insufficiency
STAAR-1 Clinical Study
To assess the effect of Aranesp on the hemoglobin of CRI subjects who are recombinant human erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy
- Conditions
- Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease, Pre-dialysis
- Trial name
- NCT00369772
- Testing
- darbepoetin alfa
- Volunteers
- 2,000 people
- Sponsor
- Amgen
Pre-Dialysis
Fixed Dose NESP Study in Subjects With CRI
Multicenter, open-label, single-arm, fixed dose study of darbepoetin alfa in subjects with Chronic Renal Insufficiency (CRI). Subjects will be screened for 2 weeks during which time blood will be drawn and vital signs will be…
- Trial name
- NCT00526929
- Testing
- darbepoetin alfa
- Volunteers
- 75 people
- Sponsor
- Amgen
Pre-Dialysis
Phase 2 Study of Darbepoetin Alfa Extended Dosing
Multicenter, open label single arm study in which 140 subjects with CRI who are currently receiving SC darbepoetin alfa once every other week will receive darbepoetin alfa once every 4 weeks for 24 weeks.
- Trial name
- NCT00527215
- Testing
- darbepoetin alfa
- Volunteers
- 98 people
- Sponsor
- Amgen
Anemia in Pre-Dialysis Patients
Clinical Study of R744 to Predialysis Patients
This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Predialysis.
- Trial name
- NCT00433615
- Testing
- R744
- Where
- 6 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Chugai Pharmaceutical
Peritoneal Dialysis Patients
Clinical Study of R744 to Peritoneal Dialysis Patients
This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Peritoneal Dialysis.
- Trial name
- NCT00433849
- Testing
- R744
- Where
- 6 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Chugai Pharmaceutical